How have ASCLF shares performed in 2024?

Ascletis Pharma's stock was trading at $0.1682 on January 1st, 2024. Since then, ASCLF stock has increased by 20.3% and is now trading at $0.2023. View the best growth stocks for 2024 here .

How do I buy shares of Ascletis Pharma?

Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ASCLF

Ascletis Pharma (ASCLF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ASCLF Stock Alerts

$0.20

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.20
▼
$0.20
50-Day Range: $0.20
▼
$0.25
52-Week Range: $0.15
▼
$0.40

Volume: N/A
Average Volume: 4,243 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get Ascletis Pharma alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Ascletis Pharma Stock (OTCMKTS:ASCLF)

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

ASCLF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASCLF Stock News Headlines

April 3, 2024 | prnewswire.com

Ascletis Announces Strategic Decisions on FXR agonist ASC42

March 10, 2024 | prnewswire.com

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 28, 2024 | seekingalpha.com

Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China

January 24, 2024 | finance.yahoo.com

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

January 23, 2024 | finance.yahoo.com

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

January 2, 2024 | finance.yahoo.com

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

December 5, 2023 | finance.yahoo.com

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

November 12, 2023 | finance.yahoo.com

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

November 8, 2023 | finance.yahoo.com

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

November 6, 2023 | finance.yahoo.com

Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D

September 28, 2023 | finance.yahoo.com

Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

September 26, 2023 | msn.com

Ascletis enrols all patients in trial of glioblastoma therapy

September 26, 2023 | finance.yahoo.com

Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

July 24, 2023 | prnewswire.com

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

June 26, 2023 | finance.yahoo.com

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

May 8, 2023 | markets.businessinsider.com

Ascletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV Infection

May 8, 2023 | finance.yahoo.com

Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

May 2, 2023 | finance.yahoo.com

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

February 27, 2023 | finance.yahoo.com

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

January 31, 2023 | finance.yahoo.com

Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

January 26, 2023 | finance.yahoo.com

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

January 17, 2023 | msn.com

Supply enters ritonavir tablets supply agreement with Simcere

January 16, 2023 | finance.yahoo.com

Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

January 15, 2023 | finance.yahoo.com

Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

January 3, 2023 | msn.com

Viking Therapeutics sues Ascletis Pharma for stealing trade secrets

See More Headlines

Receive ASCLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:ASCLF
CUSIP: N/A
CIK: N/A
Web: www.ascletis.com
Phone: 86-571-8538-9730
Fax: N/A
Employees: 219
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Jinzi Jason Wu Ph.D. (Age 60)
Founder, Chairman & CEO
Comp: $3.13M
Ms. Hejingdao Wu (Age 49)
Senior VP of Operations & Executive Director
Comp: $369.41k
Ms. Yuemei Yan (Age 54)
Senior Vice President of Clinical Development Operations
Dr. Kristjan Sigurdur Gudmundsson (Age 56)
Senior Consultant & Head of Discovery
Dr. George Zhengzhi Hill (Age 73)
Senior Consultant & Chief Medical Advisor
Mr. John P. Gargiulo M.B.A.
Chief Business Officer
Mr. Ming Fai Chung CPA (Age 44)
Company Secretary

Key Competitors

View All Competitors

ASCLF Stock Analysis - Frequently Asked Questions

How have ASCLF shares performed in 2024?: Ascletis Pharma's stock was trading at $0.1682 on January 1st, 2024. Since then, ASCLF stock has increased by 20.3% and is now trading at $0.2023.
View the best growth stocks for 2024 here.
How do I buy shares of Ascletis Pharma?: Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ASCLF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ascletis Pharma (ASCLF) Stock Price, News & Analysis

About Ascletis Pharma Stock (OTCMKTS:ASCLF)

ASCLF Stock Price History

ASCLF Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ASCLF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info